^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AZD0120

    i
    Other names: AZD0120, GC012F, GC012, Dual CAR-BCMA-19, BCMA/CD19 dual-target CAR-T cell immunotherapy, AZD-0120, GC-012, GC-012F, AZD 0120, GC 012, GC 012F
    Company:
    AstraZeneca
    Drug class:
    CD19-targeted CAR-T immunotherapy, BCMA-targeted CAR-T immunotherapy
    Related drugs:
    1d
    A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=64, Recruiting, AstraZeneca | N=20 --> 64
    Enrollment change
    |
    AZD0120
    8d
    Study of GC012F, CAR-T Therapy Targeting CD19 and BCMA in Chinese Participants With Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov)
    P1, N=9, Recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd.
    New P1 trial
    |
    AZD0120
    1m
    ZENITH: An Open-label Study of AZD0120 in Adults With Multiple Sclerosis (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    AZD0120
    3ms
    ALACRITY: A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. (clinicaltrials.gov)
    P1/2, N=91, Recruiting, Alexion Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    AZD0120
    4ms
    DURGA-3: A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=110, Recruiting, Gracell Biotechnologies (Shanghai) Co., Ltd. | Trial completion date: Jun 2026 --> Mar 2026
    Trial completion date
    |
    AZD0120
    4ms
    ALACRITY: A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis (clinicaltrials.gov)
    P1/2, N=91, Not yet recruiting, Alexion Pharmaceuticals, Inc.
    New P1/2 trial
    |
    AZD0120
    5ms
    A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Early-Line Treatment in Subjects With Multiple Myeloma (clinicaltrials.gov)
    P1, N=18, Recruiting, AstraZeneca
    New P1 trial
    |
    AZD0120
    5ms
    An Exploratory Clinical Study of GC012F Injection for Refractory gMG (clinicaltrials.gov)
    P1, N=0, Withdrawn, Zhejiang University | N=18 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    AZD0120
    7ms
    A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (clinicaltrials.gov)
    P1/2, N=150, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV • AZD0120
    8ms
    A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, AstraZeneca | Trial primary completion date: Apr 2027 --> Aug 2027
    Trial primary completion date
    |
    AZD0120
    8ms
    A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE (clinicaltrials.gov)
    P1/2, N=150, Not yet recruiting, AstraZeneca
    New P1/2 trial
    |
    cyclophosphamide • fludarabine IV • AZD0120
    11ms
    A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov)
    P1/2, N=80, Recruiting, AstraZeneca | Trial completion date: Jun 2028 --> Sep 2028 | Trial primary completion date: Dec 2026 --> Apr 2027
    Trial completion date • Trial primary completion date
    |
    AZD0120